A Step Ahead in Metastatic Renal Cell Carcinoma
- PMID: 33616313
- DOI: 10.1056/NEJMe2101777
A Step Ahead in Metastatic Renal Cell Carcinoma
Comment on
-
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Similar articles
-
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.Nat Med. 2021 Apr;27(4):586-588. doi: 10.1038/s41591-021-01320-x. Nat Med. 2021. PMID: 33820997 No abstract available.
-
Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.Clin Adv Hematol Oncol. 2015 Aug;13(8):512-3. Clin Adv Hematol Oncol. 2015. PMID: 26351813 Clinical Trial. No abstract available.
-
Novel Combination Shows Strong Antitumor Activity in Metastatic Renal Cell Carcinoma.Oncology (Williston Park). 2019 Dec 12;33(12):688722. Oncology (Williston Park). 2019. PMID: 31914201 No abstract available.
-
The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.Clin Genitourin Cancer. 2017 Oct;15(5):e903-e906. doi: 10.1016/j.clgc.2017.05.017. Epub 2017 May 25. Clin Genitourin Cancer. 2017. PMID: 28624319 Review. No abstract available.
-
Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.Int J Mol Sci. 2017 Aug 10;18(8):1736. doi: 10.3390/ijms18081736. Int J Mol Sci. 2017. PMID: 28796163 Free PMC article. Review.
Cited by
-
Sinonasal and Skull Base Metastatic Renal Cell Carcinoma: A Case Series.Cureus. 2023 Nov 13;15(11):e48757. doi: 10.7759/cureus.48757. eCollection 2023 Nov. Cureus. 2023. PMID: 38094536 Free PMC article.
-
The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?Biomedicines. 2021 Dec 31;10(1):90. doi: 10.3390/biomedicines10010090. Biomedicines. 2021. PMID: 35052770 Free PMC article. Review.
-
Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions.Cancer Diagn Progn. 2024 Sep 1;4(5):558-562. doi: 10.21873/cdp.10363. eCollection 2024 Sep-Oct. Cancer Diagn Progn. 2024. PMID: 39238630 Free PMC article. Review.
-
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.J Exp Clin Cancer Res. 2021 Aug 12;40(1):254. doi: 10.1186/s13046-021-02026-1. J Exp Clin Cancer Res. 2021. PMID: 34384473 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical